GFAP and Alzheimer disease: Notwithstanding, the fewer follow-up points for modelling the PET tracer binding than the plasma GFAP trajectories, the findings suggest that reactive brain astrogliosis measured with 11C-DED binding and plasma GFAP concentration reflect distinct aspects of the Alzheimer’s disease pathology.